Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.39 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 2/20 | 0.37 |
| ▸ | UGCG | Q16739 | 2/20 | 0.37 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6043024 | 0.92 | MCHR1 (0.41) | MCHR1MAPK14KCNH2TEAD3CYP3A4 | |
| SCHEMBL6043950 | 0.92 | MAPK14 (0.48) | MCHR1MAPK14KCNH2CYP3A4 | |
| SCHEMBL6957257 | 0.87 | MCHR1 (0.40) | MCHR1MAPK14KCNH2CYP3A4GBA1 | |
| SCHEMBL6042068 | 0.84 | MAPK14 (0.48) | MCHR1MAPK14KCNH2CYP3A4 | |
| SCHEMBL6041385 | 0.83 | REN (0.47) | MCHR1KCNH2 | |
| SCHEMBL6042508 | 0.82 | REN (0.47) | MCHR1KCNH2 | |
| SCHEMBL6950897 | 0.81 | MCHR1 (0.40) | MCHR1MAPK14KCNH2CYP3A4GBA1 | |
| SCHEMBL6954975 | 0.78 | MCHR1 (0.44) | MCHR1MAPK14KCNH2CYP3A4 | |
| SCHEMBL6044002 | 0.77 | SLC18A3 (0.38) | — | |
| SCHEMBL16670343 | 0.76 | MAPK14 (0.50) | MCHR1MAPK14KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | MCHR1 3054/4885MAPK14 4856/4885KCNH2 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.